EAM Investors LLC acquired a new position in shares of Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 185,227 shares of the company’s stock, valued at approximately $661,000. EAM Investors LLC owned about 0.25% of Eyepoint Pharmaceuticals as of its most recent filing with the SEC.
Other institutional investors have also recently made changes to their positions in the company. FineMark National Bank & Trust purchased a new position in Eyepoint Pharmaceuticals during the 2nd quarter worth $118,000. Private Advisor Group LLC purchased a new position in Eyepoint Pharmaceuticals during the 3rd quarter worth $134,000. California Public Employees Retirement System purchased a new position in Eyepoint Pharmaceuticals during the 2nd quarter worth $135,000. Creative Planning purchased a new position in Eyepoint Pharmaceuticals during the 2nd quarter worth $162,000. Finally, Bard Associates Inc. purchased a new position in Eyepoint Pharmaceuticals during the 2nd quarter worth $189,000. Institutional investors own 45.34% of the company’s stock.
NASDAQ:EYPT opened at $2.23 on Friday. The company has a quick ratio of 2.57, a current ratio of 2.57 and a debt-to-equity ratio of 0.37. Eyepoint Pharmaceuticals Inc has a fifty-two week low of $0.93 and a fifty-two week high of $3.94.
A number of equities analysts have commented on the stock. Zacks Investment Research upgraded shares of Eyepoint Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 28th. ValuEngine upgraded shares of Eyepoint Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, October 29th. HC Wainwright set a $3.00 price objective on shares of Eyepoint Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, July 27th. Finally, B. Riley upped their price objective on shares of Eyepoint Pharmaceuticals from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Tuesday, October 16th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $5.50.
WARNING: This piece was originally published by WKRB News and is owned by of WKRB News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://www.wkrb13.com/2018/11/24/eam-investors-llc-invests-661000-in-eyepoint-pharmaceuticals-inc-eypt-stock.html.
Eyepoint Pharmaceuticals Profile
EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases. The company's lead product is ILUVIEN for the treatment of diabetic macular edema; and product candidate is YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis that is in the Phase III clinical trials.
Featured Story: Moving Average (MA)
Want to see what other hedge funds are holding EYPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT).
Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.